Endocrine Abstracts

Background: In the core phase of the PAPE study until 24 weeks we have shown that switching to pasireotide LAR (PAS-LAR) in well-controlled acromegaly patients receiving combination therapy of somatostatin analogues and pegvisomant (PEGV), normalizes IGF1 levels in the majority of patients. PAS-LAR induced a significant PEGV sparing effect, but this was at the expense of a higher incidence of diabetes. This extension study until 48-weeks assesses the efficacy, safety and quali...

Introduction: Craniopharyngiomas are benign tumors in the suprasellar region that have encouraging survival rates between 77-93%. Unfortunately, long-term sequelae are frequent, resulting in excessive endocrine and metabolic morbidity, including premature cardiovascular disease and reduced bone health.Objective: To determine the prevalence of unfavorable body composition and low bone mineral density (BMD) in patients with craniopharyngioma.<p class="...

Objective: Craniopharyngioma (CP) is a benign tumor of the sellar/hypothalamic region. It is associated with endocrinopathies, which may potentially impair bone health. Our objective was to determine bone health status in CP patients.Methods: In this retrospective study, Dutch/Swedish CP patients were included if data was available on fractures, bone mineral density (BMD) (T/Z-score), or final height (age >18 years). Data is presented as mean±<s...

Background: Previous studies indicate that PAS-LAR can achieve control of insulin-like growth factor I (IGF-I) levels and may reduce tumor size, however a subset of acromegaly patients responds poorly. T2-signal intensity, somatostatin receptor (SST) subtype 2 and 5 expression, and the response to first-generation somatostatin receptor ligands (SRLs) are recognized predictors of therapy response. Valid prediction of the response to PAS-LAR can alter treatment stratification.</...

Objective: A cytosine-adenine (CA)n microsatellite repeat polymorphism in the promoter region of the insulin-like growth factor-1 (IGF-1) gene has reported to be associated with IGF-1 serum levels, birth weight, body height, bone mineral density and risk for type 2 diabetes and myocardial infarction. Carriers and non-carriers of the most frequent allele (length 192 base pairs (bp)) showed significantly different total IGF-1 serum levels. This polymorphism may direct...